Matinas BioPharma
MTNB
49 hedge funds and large institutions have $13M invested in Matinas BioPharma in 2017 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 6 closing their positions.
144% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 9
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4% more funds holding
Funds holding: 47 → 49 (+2)
0.3% less ownership
Funds ownership: 12.32% → 12.02% (-0.3%)
20% less capital inflows, than outflows
Capital inflows: $1.24M | Capital outflows: $1.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$172K |
| 2 |
Bridgeway Capital Management
Houston,
Texas
|
+$161K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$123K |
| 4 |
BlackRock
New York
|
+$108K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$95.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IFP Advisors
Tampa,
Florida
|
-$577K |
| 2 |
Alliance Wealth Management Group
Flemington,
New Jersey
|
-$516K |
| 3 |
ALPS Advisors
Denver,
Colorado
|
-$120K |
| 4 |
State Street
Boston,
Massachusetts
|
-$60.8K |
| 5 |
IIA
IPG Investment Advisors
San Diego,
California
|
-$58.7K |
MTNB Hedge Fund Activity: Q4 2017 in Review
49 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2017, worth a combined $13M — down 14% from $15.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new MTNB positions and 6 closed out — a net gain of 2 holders — while 22 added to existing stakes and 9 trimmed.
The largest buyer was American Century Companies, opening a new position worth an estimated $172K. The largest seller was IFP Advisors, cutting an estimated $577K.
- 49 institutional investors held Matinas BioPharma (MTNB) as of Q4 2017, up from 47 in Q3 2017.
- Funds reported $13M of Matinas BioPharma stock for Q4 2017, down 14% quarter-over-quarter.
- 8 funds opened new Matinas BioPharma positions in Q4 2017 and 6 closed out, a net change of +2 holders.
- The largest Matinas BioPharma buyer in Q4 2017 was American Century Companies, an estimated $172K added.
- The largest Matinas BioPharma seller in Q4 2017 was IFP Advisors, an estimated $577K sold.
Based on aggregated 13F filings for Q4 2017.